British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis

Gut

Volumn 60, Issue 12, 2011, Pages 1611-1629

  Gleeson, Dermot ^a   Heneghan, Michael A ^b  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN ANTIBODY; ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CALCIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFLAZACORT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLIXIMAB; LIVER CYTOSOLIC 1 ANTIBODY; LIVER KIDNEY MICROSOMAL 1 ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; SOLUBLE LIVER ANTIGEN LIVER PANCREAS ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER DISEASE; AMENORRHEA; ANOREXIA; ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BONE MARROW DEPRESSION; CATARACT; CELIAC DISEASE; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIAGNOSTIC TEST; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; FLU LIKE SYNDROME; FOLLOW UP; GLOMERULONEPHRITIS; HEMOLYTIC ANEMIA; HEPATITIS A; HEPATITIS C; HEPATITIS E; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JAUNDICE; JOINT SWELLING; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; MACULOPAPULAR RASH; MAINTENANCE THERAPY; MEDICAL SOCIETY; MONONEUROPATHY MULTIPLEX; MULTIPLE SCLEROSIS; NAUSEA; NONALCOHOLIC FATTY LIVER; OSTEOPOROSIS; PANCREATITIS; PATIENT MONITORING; POLYMYOSITIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PSORIASIS; PSYCHOSIS; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THYROIDITIS; UVEITIS; VITILIGO; WEIGHT GAIN; WEIGHT REDUCTION; WILSON DISEASE;

ADULT; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CYCLOSPORINE; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; PREDNISOLONE; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 80655144388     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.235259     Document Type: Review

References (308)

1. Reuben A. A sheep in wolf's clothing. Hepatology 2003;38:1596-601. (Pubitemid 37466988)
2. Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol 2010;53:191-8.
3. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97. (Pubitemid 34810370)
4. Manns MP, Czaja AJ, James D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
5. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. (Pubitemid 351632017)
6. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol 2003;18:1118-28. (Pubitemid 37410040)
7. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103. (Pubitemid 28114077)
8. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002;6:635-47.
9. Primo J, Merino C, Fernandez J, et al. [Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain)]. Gastroenterol Hepatol 2004;27:239-43.
10. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008:1-9.
11. Whitehead MW, Hainsworth I, Kingham JG. The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001;48:409-13. (Pubitemid 32269572)
12. Bittencourt PL, Palacios SA, Cancado EL, et al. Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308. J Hepatol 2001;35:24-8. (Pubitemid 32651770)
13. Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50:713-17. (Pubitemid 34407503)
14. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15. (Pubitemid 40066400)
15. D'Souza R, Sinnott P, Glynn MJ, et al. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005;25:325-30.
16. Chung HV, Riley M, Ho JK, et al. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol 2007;21:565-8. (Pubitemid 350011439)
17. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007;46:1828-35.
18. Parker DR, Kingham JG. Type I autoimmune hepatitis is primarily a disease of later life. QJM 1997;90:289-96. (Pubitemid 27180005)
19. Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45:575-83. (Pubitemid 44307378)
20. Vento S, Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 2004;3:61-9. (Pubitemid 38197972)
21. Huppertz HI, Treichel U, Gassel AM, et al. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995;23:204-8.
22. Singh G, Palaniappan S, Rotimi O, et al. Autoimmune hepatitis triggered by hepatitis A. Gut 2007;56:304.
23. Nagasaki F, Ueno Y, Mano Y, et al. A patient with clinical features of acute hepatitis E viral infection and autoimmune hepatitis. Tohoku J Exp Med 2005;206:173-9. (Pubitemid 40895047)
24. Castellote J, Guell E, Porta F. [Autoimmune hepatitis following cytomegalovirus infection]. Med Clin (Barc) 2001;117:76.
25. Kamisako T, Tsubaki K, Adachi Y. Autoimmune hepatitis after cytomegalovirus infection in a bone marrow-transplanted patient. Am J Gastroenterol 1997;92:1238-9. (Pubitemid 27304839)
26. Nobili V, Comparcola D, Sartorelli MR, et al. Autoimmune hepatitis type 1 after Epstein-Barr virus infection. Pediatr Infect Dis J 2003;22:387. (Pubitemid 36461053)
27. Bhat G, Jordan J Jr, Sokalski S, et al. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 1998;27:74-5.
28. Abe M, Furukawa S, Takayama S, et al. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med 2003;42:48-52. (Pubitemid 36267664)
29. Goldstein NS, Bayati N, Silverman AL, et al. Minocycline as a cause of druginduced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000;114:591-8.
30. Colmegna I, Perandones CE, Chaves JG. Minocycline induced lupus and autoimmune hepatitis. J Rheumatol 2000;27:1567-8.
31. Basude D, Dhawan A. Re: Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol Nutr 2007;44:389; author reply 389-90.
32. Heathcote EJ. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy? Gastroenterology 1995;108:1942-4.
33. Cholongitas E, Samonakis D, Patch D, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81:488-90. (Pubitemid 43255742)
34. Farhat BA, Johnson PJ, Williams R. Hazards of interferon treatment in patients with autoimmune chronic active hepatitis. J Hepatol 1994;20:560-1. (Pubitemid 24146375)
35. Kontorinis N, Agarwal K, Elhajj N, et al. Pegylated interferon-induced immunemediated hepatitis post-liver transplantation. Liver Transpl 2006;12:827-30.
36. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980;92:14-19. (Pubitemid 10135217)
37. Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988;8:599-606.
38. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002;4:184-6. (Pubitemid 34624691)
39. Efe C, Purnak T, Osazlan E, et al. Drug-induced autoimmune hepatitis caused by anti-tumour necrosis factor alpha agents. Hepatology 2010;52:2246-47.
40. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005;42:402-4.
41. Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 2002;97:767-8. (Pubitemid 34245921)
42. Pulicken M, Koteish A, DeBusk K, et al. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology 2006;66:1954-5. (Pubitemid 44049842)
43. Kosar Y, Sasmaz N, Oguz P, et al. Ornidazole-induced autoimmune hepatitis. Eur J Gastroenterol Hepatol 2001;13:737-9. (Pubitemid 32547878)
44. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993;38:744-51. (Pubitemid 23121285)
45. Abraham C, Hart J, Locke SM, et al. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2008;5:172-6. (Pubitemid 351344543)
46. Paredes AH, Lewis JH. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 2007;41:880-4. (Pubitemid 46752668)
47. Shalev O, Mosseri M, Ariel I, et al. Methyldopa-induced immune hemolytic anemia and chronic active hepatitis. Arch Intern Med 1983;143:592-3. (Pubitemid 13156458)
48. Luparini RL, Rotundo A, Mattace R, et al. [Possibly ranitidine-induced autoimmune hepatitis]. Ann Ital Med Int 2000;15:214-17.
49. Graziadei IW, Obermoser GE, Sepp NT, et al. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003;12:409-12. (Pubitemid 36596987)
50. Castiella A, Fernandez J, Zapata E. Autoimmune hepatitis after treatment with fluvastatin. Liver Int 2007;27:592. (Pubitemid 46534581)
51. Ganne-Carrie N, de Leusse A, Guettier C, et al. [Autoimmune hepatitis induced by fibrates]. Gastroenterol Clin Biol 1998;22:525-9.
52. Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010;44:e20-2.
53. Berry PA, Smith-Laing G. Hepatitis A vaccine associated with autoimmune hepatitis. World J Gastroenterol 2007;13:2238-9. (Pubitemid 46851164)
54. Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 1997;92:703-4. (Pubitemid 27184395)
55. Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol 2001;96:1654-5. (Pubitemid 32455119)
56. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040-8.
57. Vergani D, Choudhuri K, Bogdanos DP, et al. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002;6:727-37.
58. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008;14:3306-12.
59. Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009;29:241-53.
60. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004;53:599-608. (Pubitemid 38372988)
61. Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48:140-7. (Pubitemid 350191991)
62. Muratori P, Granito A, Quarneti C, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009;50:1210-18.
63. Hay JE, Czaja AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989;9:193-7. (Pubitemid 19063300)
64. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62. (Pubitemid 40911311)
65. Kogan J, Safadi R, Ashur Y, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35:75-81. (Pubitemid 34663355)
66. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21:866-71. (Pubitemid 24374156)
67. Al-Chalabi T, Underhill JA, Portmann BC, et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol 2008;6:1389-95; quiz 1287.
68. Werner M, Wallerstedt S, Lindgren S, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010;45:457-67.
69. Herzog D, Rasquin-Weber AM, Debray D, et al. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997;27:578-82. (Pubitemid 27390907)
70. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-31. (Pubitemid 38834047)
71. Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23:1347-53.
72. Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003. (Pubitemid 47163192)
73. Lohse A, Mieli-Vergani G. Autoimmune hepatitis. J Hepatol 2011;55:171-82.
74. Bernal W, Ma Y, Smith HM, et al. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol 2007;47:664-70. (Pubitemid 47503423)
75. Iwai M, Jo M, Ishii M, et al. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res 2008;38:784-9. (Pubitemid 352015629)
76. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-85.
77. Lewin M, Vilgrain V, Ozenne V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009;50:528-37.
78. Abdalian R, Dhar P, Jhaveri K, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47:949-57. (Pubitemid 351449686)
79. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
80. Anagnostopoulos GK, Margantinis G, Tsiakos S, et al. Postinfantile giant-cell hepatitis associated with ulcerative colitis and autoimmune hepatitis. J Gastroenterol Hepatol 2006;21:1863-4. (Pubitemid 44657015)
81. Seibold F, Weber P, Jenss H, et al. Autoimmune hepatitis in inflammatory bowel disease: report of two unusual cases. Z Gastroenterol 1997;35:29-32. (Pubitemid 27064435)
82. Thevenot T, Mathurin P, Di Martino V, et al. [Celiac disease and liver involvement]. Gastroenterol Clin Biol 2003;27:28-42.
83. McFarlane IG. Lessons about antibodies in autoimmune hepatitis. Lancet 2000;355:1475-6.
84. Kaukinen K, Halme L, Collin P, et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8. (Pubitemid 34267270)
85. Villalta D, Girolami D, Bidoli E, et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 2005;19:6-10. (Pubitemid 40170594)
86. Nobili V, Devito R, Comparcola D, et al. Juvenile idiopathic arthritis associated with autoimmune hepatitis type 2. Ann Rheum Dis 2005;64:157-8. (Pubitemid 40075299)
87. Matsumoto T, Morizane T, Aoki Y, et al. Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome. Pathol Int 2005;55:70-6. (Pubitemid 40343726)
88. Irving KS, Sen D, Tahir H, et al. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus: a retrospective review of cases. Rheumatology (Oxford) 2007;46:1171-3. (Pubitemid 47050624)
89. Paul K, Wille L, Feist D, et al. [Fibrosing alveolitis in a 7-year-old girl with autoimmune hemolytic anemia and autoimmune hepatitis]. Pneumologie 1991;45:928-31.
90. Takahashi K, Takasaki S, Morita C, et al. Autoimmune hepatitis with membranous glomerulonephritis. J Gastroenterol Hepatol 2001;16:356-9. (Pubitemid 32374858)
91. Yamaike N, Saigo K, Imoto S, et al. Autoimmune hepatitis accompanied by idiopathic thrombocytopenic purpura and Sjogren's syndrome. Intern Med 2002;41:72. (Pubitemid 34196223)
92. Gurudu SR, Mittal SK, Shaber M, et al. Autoimmune hepatitis associated with autoimmune hemolytic anemia and anticardiolipin antibody syndrome. Dig Dis Sci 2000;45:1878-80.
93. Sacher M, Blumel P, Thaler H, et al. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J Hepatol 1990;10:364-9. (Pubitemid 20162748)
94. Romanelli RG, La Villa G, Almerigogna F, et al. Uveitis in autoimmune hepatitis: a case report. World J Gastroenterol 2006;12:1637-40.
95. Ko KF, Ho T, Chan KW. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 1995;59:558-9.
96. Nunez O, de Andres C, Alvarez E, et al. [Autoimmune hepatitis in patients with a diagnosis of multiple sclerosis]. Gastroenterol Hepatol 2004;27:521-4.
97. Luth S, Birklein F, Schramm C, et al. Multiplex neuritis in a patient with autoimmune hepatitis: a case report. World J Gastroenterol 2006;12:5396-8. (Pubitemid 44501790)
98. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007;46:1641-7. (Pubitemid 350018483)
99. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37:302-8. (Pubitemid 34969945)
100. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992;103:1041-7.
101. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
102. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology 1993;18:998-1005.
103. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
104. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76. (Pubitemid 351975541)
105. Yeoman AD, Westbrook RH, Al-Chalabi T, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50:538-45.
106. McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002;6:605-21.
107. Floreani A, Niro G, Rosa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006;24:1051-7. (Pubitemid 44386530)
108. Bogdanos DP, Invernizzi P, Mackay IR, et al. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008;14:3374-87.
109. Czaja AJ, Cassani F, Cataleta M, et al. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997;42:1688-96. (Pubitemid 27394592)
110. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394-401. (Pubitemid 29113226)
111. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
112. Kerkar N, Choudhuri K, Ma Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003;170:1481-9. (Pubitemid 36139518)
113. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31:635-40. (Pubitemid 29487684)
114. Manns M, Gerken G, Kyriatsoulis A, et al. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-4. (Pubitemid 17009789)
115. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64. (Pubitemid 34183971)
116. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355:1510-15.
117. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000;33:208-15. (Pubitemid 30485224)
118. Targan SR, Landers C, Vidrich A, et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;108:1159-66.
119. Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997;25:1105-7. (Pubitemid 27199935)
120. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677-83. (Pubitemid 39297806)
121. O'Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008;48:550-6.
122. Farias AQ, Goncalves LL, Bittencourt PL, et al. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. J Gastroenterol Hepatol 2006;21:887-93. (Pubitemid 43793289)
123. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990;65:23-30. (Pubitemid 20061922)
124. Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993;104:1755-61. (Pubitemid 23235469)
125. Johnson PJ, McFarlane IG, McFarlane BM, et al. Auto-immune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional autoantibodies. J Gastroenterol Hepatol 1990;5:244-51. (Pubitemid 20375184)
126. Kaymakoglu S, Cakaloglu Y, Demir K, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol 1998;28:78-83. (Pubitemid 28122503)
127. Gassert DJ, Garcia H, Tanaka K, et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci 2007;52:2433-7. (Pubitemid 47246512)
128. Heringlake S, Schutte A, Flemming P, et al. Presumed cryptogenic liver disease in Germany: high prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology. Z Gastroenterol 2009;47:417-23.
129. Czaja AJ, Carpenter HA, Santrach PJ, et al. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996;24:52-9. (Pubitemid 26035978)
130. McFarlane IG. Autoantibodies in alcoholic liver disease. Addiction Biol 2000;5:141-51. (Pubitemid 30229457)
131. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99:1316-20. (Pubitemid 39062269)
132. Czaja AJ, Beaver SJ, Wood JR, et al. Frequency and significance of serum alphafetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987;93:687-92. (Pubitemid 17155992)
133. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-32. (Pubitemid 24002801)
134. Boyer JL. Chronic hepatitis: a perspective on classification and determinants of prognosis. Gastroenterology 1976;70:1161-71.
135. Paronetto F, Rubin E, Popper H. Local formation of gamma-globulin in the diseased liver and its relation to hepatic necrosis. Lab Invest 1962;11:150-8.
136. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20. (Pubitemid 24166476)
137. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
138. Hofer H, Oesterreicher C, Wrba F, et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006;59:246-9. (Pubitemid 43344883)
139. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23:116-23. (Pubitemid 37265783)
140. Pratt DS, Fawaz KA, Rabson A, et al. A novel histological lesion in glucocorticoidresponsive chronic hepatitis. Gastroenterology 1997;113:664-8. (Pubitemid 27351796)
141. Singh R, Nair S, Farr G, et al. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97:2670-3.
142. Okano N, Yamamoto K, Sakaguchi K, et al. Clinicopathological features of acuteonset autoimmune hepatitis. Hepatol Res 2003;25:263-70. (Pubitemid 36546352)
143. Phillips MJ, Blendis LM, Poucell S, et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Engl J Med 1991;324:455-60.
144. Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992;16:327-33.
145. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2004;20:231-40. (Pubitemid 38526773)
146. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-65. (Pubitemid 32927988)
147. Czaja AJ, Muratori P, Muratori L, et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004;24:322-9. (Pubitemid 39162072)
148. Baggenstoss AH, Soloway RD, Summerskill WH, et al. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol 1972;3:183-98.
149. Schalm SW, Korman MG, Summerskill WH, et al. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977;22:973-80. (Pubitemid 8225482)
150. Cooksley WG, Bradbear RA, Robinson W, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 1986;6:345-8. (Pubitemid 16086616)
151. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988;95:448-53.
152. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33:537-42.
153. Talwalkar JA, Keach JC, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191-7. (Pubitemid 34478121)
154. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48:1540-8.
155. Höroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 140:1980-9.
156. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology 2011;140:1472-80.
157. Gatselis NK, Zachou K, Papamichalis P, et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis 2010;42:807-12.
158. Qiu D, Wang Q, Wang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol 2011;54:340-7.
159. Keating JJ, O'Brien CJ, Stellon AJ, et al. Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: an analysis of 204 patients. Q J Med 1987;62:59-66. (Pubitemid 17015916)
160. De Groote J, Fevery J, Lepoutre L. Long term follow up of chronic active hepatitis of moderate severity. Gut 1978;19:510-13. (Pubitemid 8363910)
161. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009;29:816-23.
162. Dufour JF, Zimmermann M, Reichen J. Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol 2002;37:748-52. (Pubitemid 35404212)
163. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-85.
164. Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21:78-83. (Pubitemid 10157086)
165. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
166. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
167. Summerskill WH, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-83.
168. Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993;18:342-52. (Pubitemid 23279723)
169. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
170. Schramm C, Weiler-Normann C, Wiegard C, et al. Treatment response in patients with autoimmune hepatitis. Hepatology 2010;52:2247-8.
171. Miyake Y, Iwasaki Y, Terada R, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24:1197-205. (Pubitemid 44427507)
172. Verma S, Gunuwan B, Mendler M, et al. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99:1510-16. (Pubitemid 39180099)
173. Muratori L, Muratori P, Lanzoni G, et al. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology 2010;52:1857.
174. Tan P, Marotta P, Ghent C, et al. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int 2005;25:728-33. (Pubitemid 41038653)
175. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998;42:599-602.
176. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-64. (Pubitemid 34791458)
177. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-5.
178. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102(5):1005-12. (Pubitemid 46698236)
179. Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-7. (Pubitemid 14051128)
180. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57. (Pubitemid 26071852)
181. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984;87:1222-7. (Pubitemid 15201418)
182. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009;51:161-7.
183. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39:1631-8. (Pubitemid 38702664)
184. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-15. (Pubitemid 46534573)
185. Cattan P, Berney T, Conti F, et al. Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int 2002;15:34-8. (Pubitemid 36055897)
186. Czaja AJ, Wang KK, Shiels MT, et al. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J Hepatol 1993;17:180-6. (Pubitemid 23054484)
187. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8:781-4.
188. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63.
189. Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-91. (Pubitemid 44307381)
190. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51:968-75. (Pubitemid 44030824)
191. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005;100:1121-5. (Pubitemid 40769051)
192. Eland IA, van Puijenbroek EP, Sturkenboom MJ, et al. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 1999;94:2417-22. (Pubitemid 29420667)
193. DePinho RA, Goldberg CS, Lefkowitch JH. Azathioprine and the liver. Evidence favouring idiosyncratic mixed cholestatic-herpatocellular injury in humans. Gastroenterology 1984;86:162-5. (Pubitemid 14177332)
194. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
195. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003;52:140-2. (Pubitemid 36020781)
196. Hindorf U, Jahed K, Bergquist A, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol 2010;52:106-11.
197. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-21.
198. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of endstage liver disease. Hepatology 2007;46:1138-45. (Pubitemid 350144778)
199. Yeoman AD, Westbrook RH, Zen Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011;53:926-34.
200. Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976;8:221-7.
201. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981;80:687-92. (Pubitemid 11137747)
202. Luth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42:926-30.
203. Hoeroldt B, Dube A, McFarlane E, et al. Persistent histological inflammation in autoimmune hepatitis despite biochemical remission. Frequency and prognostic significance. Gut 2009;59:A18.
204. Dhaliwal H, Hoeroldt B, Dube A, et al. What is the optimal histological endpoint of treatment in autoimmune hepatitis? Gut 2011;60:A229.
205. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15. (Pubitemid 34267273)
206. Gardiner SJ, Gearry RB, Burt MJ, et al. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur J Gastroenterol Hepatol 2008;20:1238-42.
207. Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103:3063-70.
208. Hegarty JE, Nouri Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-9. (Pubitemid 13007694)
209. Czaja AJ, Ludwig J, Baggenstoss AH, et al. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5-9. (Pubitemid 11212890)
210. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-7.
211. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987;92:215-19. (Pubitemid 17207684)
212. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13. (Pubitemid 34032538)
213. Al-Chalabi T, Heneghan MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved? Am J Gastroenterol 2007;102:1013-15. (Pubitemid 46698235)
214. Stellon AJ, Hegarty JE, Portmann B, et al. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985;1:668-70. (Pubitemid 15134821)
215. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003;35:1714-16. (Pubitemid 37093684)
216. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-92. (Pubitemid 19005407)
217. Wang KK, Czaja AJ, Beaver SJ, et al. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989;10:39-43. (Pubitemid 19170001)
218. Hoeroldt B, Farquharson N, Shepherd K, et al. Cancer in autoimmune hepatitis. Gut 2008;52:A79.
219. Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388-93.
220. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990;11:1044-9. (Pubitemid 20221043)
221. Kanzler S, Lohr H, Gerken G, et al. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001;39:339-41, 344-8.
222. Poulsen LO, Thulstrup AM, Mellemkjaer L, et al. Mortality and causes of death in patients with "lupoid hepatitis". A long-term follow-up study in Denmark. Dan Med Bull 2002;49:263-5.
223. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:646-52. (Pubitemid 38367787)
224. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005;43:951-7. (Pubitemid 41627979)
225. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000;45:1944-8.
226. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008;103:1944-51.
227. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48:863-70.
228. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271-8. (Pubitemid 350144791)
229. Pares A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol 2006;45:445-53. (Pubitemid 44160631)
230. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941-66. (Pubitemid 37070710)
231. Royal College of Physicians. Glucocorticoid Induced Osteoporosis: Guidelines for Prevention and Treatment. London: Royal College of Physicians, 2002.
232. Person JL, McHutchison JG, Fong TL, et al. A case of cyclosporine- sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993;17:317-20. (Pubitemid 23360387)
233. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7.
234. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61.
235. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7. (Pubitemid 32523281)
236. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7. (Pubitemid 29071183)
237. Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43:635-9. (Pubitemid 44863691)
238. Debray D, Maggiore G, Girardet JP, et al. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135:111-14. (Pubitemid 30180574)
239. Sciveres M, Caprai S, Palla G, et al. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents. Aliment Pharmacol Ther 2004;19:209-17. (Pubitemid 38174890)
240. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
241. Heneghan MA, Rizzi P, McFarlane IG, et al. Low dose tacrolimus as threatment of severe autoimmune hepatitis: potential role in remission induction. Gut 1999;44 (Suppl 1):A61.
242. Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95:3238-41.
243. Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9. (Pubitemid 39274185)
244. Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in nontransplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005;25:723-7. (Pubitemid 41038652)
245. Larsen FS, Vainer B, Eefsen M, et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6. (Pubitemid 47064587)
246. Geier A, Gartung C, Dietrich CG, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003;9:2681-5. (Pubitemid 38054439)
247. Csepregi A, Rocken C, Treiber G, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006;12:1362-6.
248. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8:585-90. (Pubitemid 24381357)
249. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-16.
250. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008;22:388-92. (Pubitemid 351772333)
251. Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25:927-34. (Pubitemid 41404011)
252. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999;91:630-8. (Pubitemid 29503032)
253. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5. (Pubitemid 30663373)
254. Devlin SM, Swain MG, Urbanski SJ, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6. (Pubitemid 38801788)
255. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-25. (Pubitemid 41361901)
256. Hlivko JT, Shiffman ML, Stravitz RT, et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6:1036-40.
257. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007;5:799-802. (Pubitemid 47031057)
258. Sharzehi K, Huang MA, Schreibman IR, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010;24:588-92.
259. Zachou K, Gatselis N, Papadamou G, et al. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55:636-46.
260. Buell C, Koo J. Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol 2008;7:741-8.
261. Brunt EM, Di Bisceglie AM. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum Pathol 2004;35:509-12. (Pubitemid 38507090)
262. Dasgupta N, Gelber AC, Racke F, et al. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 2005;14:910-13. (Pubitemid 41736374)
263. Vernino S, Salomao DR, Habermann TM, et al. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005;65:639-41. (Pubitemid 41170735)
264. Finelli PF, Naik K, DiGiuseppe JA, et al. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus 2006;15:886-8. (Pubitemid 46044922)
265. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30:1381-6.
266. Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitisereport of three cases. Z Gastroenterol 1997;35:571-8.
267. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3. (Pubitemid 28559070)
268. Weiler-Normann C, Wiegard C, Schramm C. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2010;104:2877-8.
269. Barth E, Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol 2010;4:502-9.
270. Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48:97-102. (Pubitemid 32042648)
271. Samuel D, Riordan S, Strasser S, et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol 2004;2:622-4. (Pubitemid 38834046)
272. Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101:556-60. (Pubitemid 43340932)
273. Werner M, Bjornsson E, Prytz H, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42:986-91. (Pubitemid 47037128)
274. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003;124:9-17. (Pubitemid 36055333)
275. Buchel E, Van Steenbergen W, Nevens F, et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002;97:3160-5. (Pubitemid 35424590)
276. Christopher V, Al-Chalabi T, Richardson PD, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl 2006;12:1138-43. (Pubitemid 44063790)
277. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31. (Pubitemid 41772537)
278. Ahmed M, Mutimer D, Hathaway M, et al. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplant Proc 1997;29:496. (Pubitemid 27123503)
279. Roberts MS, Angus DC, Bryce CL, et al. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:886-97. (Pubitemid 38979259)
280. Vogel A, Heinrich E, Bahr MJ, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18:62-9. (Pubitemid 38195546)
281. Khalaf H, Mourad W, El-Sheikh Y, et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant Proc 2007;39:1166-70. (Pubitemid 46764831)
282. Schramm C MB, O'Grady JG, Buckles J, et al. Long-term outcome of patients transplanted for autoimmune hepatitis: analysis of the European Liver Transplant Registry. J Hepatol 2008;48:S47.
283. Neuberger J, Portmann B, Calne R, et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 1984;37:363-5. (Pubitemid 14105426)
284. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-24. (Pubitemid 44911808)
285. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30:131-41. (Pubitemid 29023662)
286. Milkiewicz P, Hubscher SG, Skiba G, et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 1999;68:253-6. (Pubitemid 29360286)
287. Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998;66:1645-50. (Pubitemid 29034985)
288. Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000;32:693-700.
289. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-45. (Pubitemid 28405409)
290. Demetris AJ, Adeyi O, Bellamy CO, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006;44:489-501. (Pubitemid 44214890)
291. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13. (Pubitemid 28064165)
292. Jones DE, James OF, Portmann B, et al. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 1999;30:53-7. (Pubitemid 29300568)
293. Heneghan MA, Portmann BC, Norris SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34:464-70. (Pubitemid 32791325)
294. Aguilera I, Wichmann I, Sousa JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001;126:535-9. (Pubitemid 34008729)
295. Spada M, Bertani A, Sonzogni A, et al. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis. Transplant Proc 2001;33:1747-8. (Pubitemid 32238048)
296. Chazouilleres O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296-301. (Pubitemid 28363652)
297. Poupon R, Chazouilleres O, Corpechot C, et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44:85-90. (Pubitemid 44049141)
298. Chazouilleres O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44:400-6. (Pubitemid 43069223)
299. Lohse AW, zum Buschenfelde KH, Franz B, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84. (Pubitemid 29168740)
300. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002;35:409-13.
301. Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007;102:1244-50. (Pubitemid 46802005)
302. Al-Chalabi T, Portmann BC, Bernal W, et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28:209-20. (Pubitemid 351861961)
303. van Buuren HR, van Hoogstraten HJE, Terkivatan T, et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33:543-8.
304. Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369-76. (Pubitemid 26181218)
305. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-17. (Pubitemid 36775813)
306. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53. (Pubitemid 32185215)
307. Abdo AA, Bain VG, Kichian K, et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36:1393-9. (Pubitemid 35403530)
308. Luth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol 2009;43:75-80.